Top Markets
#1 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +596.82%
#2 Phala Phala +68.04%
#3 Bitway Bitway +35.59%
#4 龙虾 (Lobster) 龙虾 (Lobster) +25.84%
#5 ARK ARK +25.10%
#6 Backpack Backpack +23.94%
#7 Mubarak Mubarak +21.40%
#8 Aerodrome Finance Aerodrome Finance +20.71%
#9 The Black Bull The Black Bull +19.54%
#10 APEX APEX +18.93%
Coin of the day
Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain)
Settings
Language
ENGLISH
Currency
USD
Theme
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Rank in Stocks #36735
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to... Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Share Price
$0.2483
Last synced: 2026-07-31
Market Cap
$2.30M
Change (1 day)
-3.39%
Change (1 year)
-89.01%
Country
US
Trade Ensysce Biosciences, Inc. (ENSC)

Category

Healthcare
Revenue for Ensysce Biosciences, Inc. (ENSC)
Revenue in Jun 2026 TTM: $1.16M
According to Ensysce Biosciences, Inc. latest financial reports the company's current revenue (TTM) is $1.16M. In 2023 the company made a revenue of $2.23M a decrease compared to the revenue in the year 2022 that was $2.52M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Ensysce Biosciences, Inc. from 2017 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $1.16M -77.65%
2024 $5.21M 133.53%
2023 $2.23M -11.59%
2022 $2.52M -28.54%
2021 $3.53M -10.18%
2020 $3.93M 122.86%
2019 $1.76M 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 1,084,168.43%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 191,257.15%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 517,052.77%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 1,352,139.48%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH